Abonneer je op onze nieuwsbrief om op de hoogte te blijven
Klik hier
  • BLS
  • Spotlight

Safety guide: chemical pharmaceutical industry

BLS Safety Guide: chemical-pharmaceutical industry


A guide written by Dr. Antonio Moffa, Dr. Claudia Beccaria and Lucrezia Giorgi of the Unit of Integrated Therapies in Otolaryngology at the University Polyclinic Campus Bio-Medical Foundation in Rome.

 

The manufacture of pharmaceutical products involves the use of numerous chemicals, obtained by fermentation, organic or biological synthesis, which can sometimes be used in very high concentrations and risk endangering the health or safety of operators.

 

 

The handling of chemical or biological substances used in drugs and reagents involves acute and chronic risks. The toxic effects, such as mutagenesis and neurotoxicity, are often irreversible and may persist over time. The most commonly used products include solvents, corrosive acids and caustic bases. It is essential to manage these risks to ensure the safety of operators and the public.

Granulating, mixing and wet coating operations can expose operators to high solvent vapours. During other steps such as distribution, drying and mixing, airborne particles may increase exposure. Thehandling and storage of these products pose risks of exposure through inhalation, ingestion or direct contact during plant breakdowns. These risks must be carefully managed to prevent harmful exposures and related diseases. Below are the risks related to the various work steps of toxic products and associated diseases. (see table)

 

 

Toxicity risks depend on the physical and chemical properties of the products and the routes of entry into the body. Workers in pharmaceutical industries may be exposed to chemicals through inhalation, skin contact, ingestion and eye projection. Common occupational diseases in the industry include osteomuscular, respiratory, ear problems, tumours and other diseases. Exposures to dust, gaseous compounds and solvent vapours can cause allergic reactions, respiratory disorders and cancers. The substances most frequently implicated as causes of occupational diseases include asbestos, hydrocarbon derivatives and other specific chemicals.

 

 

In pharmaceutical industries, risk prevention is based on a number of collective and individual measures. Collective measures include adequate infrastructure such as well-designed rooms, safe work plans and effective ventilation devices to capture pollutants. Automation of operations through remote-controlled and controlled systems reduces the risk of operator exposure. In addition, hygienic equipment such as safety showers and eye wash stations are essential, along with hygienic practices such as hand washing.

 

In order to protect operators from chemical hazards arising from pharmaceuticals, excipients, solvents and disinfectants, the use of personal protective equipment is required. These include:

- Hand protectors, protecting against chemicals, heat, frost and potential allergens.
- Eye and face protectors, protecting against splashes, drops, dusts and irritating gases.
- Body protectors, especially in case of exposure to corrosive substances.
- Respiratory devices, protecting against the harmful effects of gases, vapours, dusts, fibres, fumes and mists.

Furthermore, it is essential that operators receive training and detailed information on the risks associated with the products and materials used, so that they can adopt safe behaviour while working.

 

Recommended products:

 

 

 

Stay informed
Stay safe.

 

Gerelateerde artikelen

oktober 11, 2022 Bacteria

Cosa sappiamo sui batteri patogeni? I batteri patogeni costituiscono tra le forme viventi più diffuse sulla Terra. I batteri patogeni sono responsabili in tutto il mondo di malattie e conseguenze anche su scala epidemica. Si propagano attraverso l’aria, l’acqua e il suolo. Organismi a cellula procariota, solitamente unicellulari, oscillano tra 0,2 e 10 µm e […]

Link
november 7, 2023 Safety guide: Asbestos

BLS Safety Guide: Amianto Guida realizzata dalla monografia redatta dal Dott. Antonio Moffa, dalla Dott.ssa Claudia Beccaria e dall’Ing. Lucrezia Giorgi dell’Unità di Terapie Integrate in Otorinolaringoiatria della Fondazione Policlinico Universitario Campus Bio-Medico di Roma.   Nel quinquennio 2016-2020 sono stati mediamente circa 1.500 l’anno i lavoratori a cui è stata riconosciuta una malattia asbesto-correlata. […]

Link
februari 24, 2023 Product focus | New BLS Zer0

I facciali filtranti BLS Zer0 cambiano volto La massima protezione incontra la sostenibilità   La protezione di un FFP3 con la resistenza respiratoria di un FFP1. I facciali filtranti a coppa della serie BLS Zer0, con protezione FFP3, rappresentano uno dei principali prodotti della gamma BLS. Con o senza valvola di espirazione Eolo, con o […]

Link

Abonneer op onze nieuwsbrief

Ontvang updates over onze evenementen, nieuws, catalogus en aankomende initiatieven.
Abonneren

Neem contact op

Laat uw bericht achter, wij antwoorden binnen 48 uur.
Vraag informatie aan

BLS S.R.L.
Società a Socio Unico
via dei Giovi, 41 - 20032 Cormano (MI) - Italia
t/f +39 02 39310212 / 66200473
info@blsgroup.it
Privacy Policy - Cookie Policy

Geregistreerd kantoor
via dei Giovi, 41 – 20032 Cormano (MI) - Italia
Capitale Sociale | Share Capital: Euro 600.000,00 i.v.
C.C.I.A.A. - R.E.A.: MI 1186898
Partita IVA | VAT N°: IT12296780153
C.F. e Iscrizione al Registro delle Imprese di Milano: 07822320151

BLS IBERIA / Av. Pau Casals, 8 08182 Sant Feliu de Codines Barcelona - Spain
BLS NORTHWEST / Reeweg, 132 3343 AP H.I. Ambacht Rotterdam - The Netherlands
BLS DO BRASIL / Rua Alvarenga Peixoto, 307 05095-010 Sao Paulo - SP - Brazil
BLS GERMANY / Steindeich 1a, 25377 Kollmar - Germany
BLS FRANCE / 18 Porte du Grand Lyon 01700 Neyron - France

crossmenuchevron-downcross-circle
NL